RE: Microperimetry and the diagnosis of antimalarial maculopathy

Canadian Journal of Ophthalmology

Volumn 49, Issue 3, 2014, Pages 307-308

  Easterbrook, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; ANTIRHEUMATIC AGENT;

AUTOFLUORESCENCE; DEPIGMENTATION; ELECTRORETINOGRAM; HUMAN; LETTER; MICROPERIMETRY; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULOPATHY; RETINOPATHY; SCOTOMA; SENSITIVITY AND SPECIFICITY; VISION TEST; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; MALE; METHODOLOGY; NOTE; PERIMETRY; RETINA; RETINA DISEASE; VISUAL FIELD;

ANTIRHEUMATIC AGENTS; CHLOROQUINE; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; RETINA; RETINAL DISEASES; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84908132416     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2014.03.016     Document Type: Letter

References (4)

1. Martinez-Costa L, Ibanez Maria V, Murcia-Bello C, et al. Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. Can J Ophthalmol. 2013; 48: 400-5.
2. Marmor ME, Kellner UK, Lai Ty, Lysons JS, Mieler WF. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine. Ophthalmology. 2011; 118: 415-22.
3. Navajas E, Farahvash S, Boyd S, Brent M, Easterbrook M. MOCT, autofluoresence and the mfERG in the diagnosis of early anti-malarial toxicity. Annual meeting Canadian Ophthalmological Society. June 28, 2012.
4. Easterbrook M. Monitoring patients on anti-malarials: where are we now? Can J Ophthalmol. 2012; 47: 465-70.